Thakur Sameer, Choong Emma, Balasooriya Anuradha, Spelman Tim, Wright Gavin, Choong Peter
Department of Cardiothoracic Surgery, St Vincent's Hospital Melbourne, Melbourne, Victoria, Australia.
Department of Surgery, St. Vincent's Hospital Melbourne, The University of Melbourne, Melbourne, Victoria, Australia.
ANZ J Surg. 2022 Oct;92(10):2613-2619. doi: 10.1111/ans.17904. Epub 2022 Jul 11.
Chest wall sarcomas are a rare group of tumours. Surgical resection is considered the mainstay of curative treatment, however, resection and reconstruction of chest wall defects presents complex issues for the clinician.
A retrospective analysis of 59 patients undergoing surgical management of chest wall sarcoma between December 1996 and July 2020 was conducted across a multidisciplinary sarcoma service in Melbourne, Australia. Patient demographics, pathologic data, and long-term outcomes were recorded.
Mean age at surgery was 48.4 years (SD 18.3), and 66.1% were male. Median follow-up was 29 months (IQR 11.8, 51.0 months). Fifty-one patients presented with primary tumours, while the others had secondary tumours resected. Most tumours arose in bone (72.9%) as opposed to soft tissues (27.1%). Chondrosarcoma was the most common histologic subtype (50.8%). The most common reconstructive techniques involved the use of mesh (79.7%) or mesh supplemented with bone cement (33.9%). Overall survival at 1 and 5 years was 92% and 70%, respectively. Seven patients died of metastatic sarcoma during the follow up period with a median survival time of 27 months. Twelve patients had evidence of disease recurrence during the follow-up period. Stage 4 disease, soft tissue tumours, secondary tumours, leiomyosarcoma and UPS subtypes, and plating reconstruction were associated with increased disease recurrence.
The results suggest that outcomes for chest wall sarcoma are similar to extremity sarcomas and may be treated in a similar manner. Patients requiring adjuvant radiotherapy and those who develop disease-recurrence are more likely to have worse overall survival outcome despite complete surgical resection.
胸壁肉瘤是一组罕见的肿瘤。手术切除被认为是根治性治疗的主要手段,然而,胸壁缺损的切除和重建给临床医生带来了复杂的问题。
对1996年12月至2020年7月期间在澳大利亚墨尔本一个多学科肉瘤治疗中心接受胸壁肉瘤手术治疗的59例患者进行回顾性分析。记录患者的人口统计学资料、病理数据和长期预后。
手术时的平均年龄为48.4岁(标准差18.3),男性占66.1%。中位随访时间为29个月(四分位间距11.8,51.0个月)。51例患者为原发性肿瘤,其余患者为继发性肿瘤切除。大多数肿瘤起源于骨骼(72.9%),而非软组织(27.1%)。软骨肉瘤是最常见的组织学亚型(50.8%)。最常见的重建技术包括使用网片(79.7%)或补充骨水泥的网片(33.9%)。1年和5年的总生存率分别为92%和70%。7例患者在随访期间死于转移性肉瘤,中位生存时间为27个月。12例患者在随访期间有疾病复发的证据。4期疾病、软组织肿瘤、继发性肿瘤、平滑肌肉瘤和未分化多形性肉瘤亚型以及钢板重建与疾病复发增加相关。
结果表明,胸壁肉瘤的预后与肢体肉瘤相似,可能采用相似的治疗方式。尽管进行了完整的手术切除,但需要辅助放疗的患者和发生疾病复发的患者总体生存结果更可能较差。